Outro has raised $7 million across pre-seed and seed funding rounds, with participation from Listen Ventures, Cake Ventures, Jason Calacanis’s LAUNCH, Actions Capital, Hannah Grey VC, SemperVirens, Brock Recovery Group and Pave Health Ventures. The company did not disclose a lead investor or how the financing was divided between the two rounds.
Founded in 2022 and headquartered in New York, Outro develops a healthcare platform focused on deprescribing, helping patients taper psychiatric medications under clinical supervision. The company is led by co-founder and CEO Brandon Goode and co-founder Dr. Mark Horowitz. Its approach combines clinicians trained in deprescribing, individualized tapering protocols, patient monitoring, psychosocial support and technology, with an initial focus on antidepressants.
Outro’s Taper Management program is currently available in 14 US states. The company plans to use the new capital to expand its clinician network, develop AI-supported workflows for deprescribing, extend its tapering model to additional drug classes and expand partnerships with universities and advocacy organizations.
